Skip to main content

Together we are beating cancer

Donate now

Targeted therapies

Showing 12 out of 70 results

The National Institute of Health and Care Excellence (NICE) has approved the use of pemigatinib in adults with a rare type of bile duct cancer that has continued to advance or spread after initial chemotherapy. The National Institute of Health and Care Excellence (NICE) has approved the use of pemigatinib in adults with a rare type of bile duct cancer that has continued to advance or spread after initial chemotherapy.

by Harry Jenkins | News | 22 July 2021

22 July 2021

Lung adenocarcinoma cells
  • Science & Technology
  • Health & Medicine

ASCO 2021 news: follow-up treatments pave the way

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented. One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

by Harry Jenkins | Analysis | 9 June 2021

9 June 2021

Lung cancer cell

The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma. The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.

by Cancer Research UK | News | 21 January 2021

21 January 2021